flutamide has been researched along with Soft Tissue Neoplasms in 4 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo." | 5.08 | Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. ( Blumenstein, BA; Bueschen, AJ; Crawford, ED; Culkin, DJ; Eisenberger, MA; Loehrer, PJ; Lowe, BA; McLeod, DG; Miller, G; Sears, K; Thompson, IM; Wilding, G, 1998) |
| "For good prognosis metastatic prostate cancer patients under anti-androgen treatment, PSA response at 6 months with cut-off levels of < or = 1 ng/ml and < or = 10 ng/ml is prognostic for survival." | 2.71 | Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). ( Collette, L; de Reijke, TM; Schröder, FH, 2003) |
| ") monotherapy at a daily dose of 100 mg, which is the most commonly used dosage in Japan for patients with prostatic cancer." | 2.67 | A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group. ( Akaza, H; Aso, Y; Koiso, K; Kotake, T; Usami, M, 1993) |
| "Flutamide appears to be a safe antiandrogen, usually effective in the management of patients with advanced prostatic cancer who have had no prior endocrine therapy." | 2.65 | Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. ( Sogani, PC; Vagaiwala, MR; Whitmore, WF, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Collette, L | 1 |
| de Reijke, TM | 1 |
| Schröder, FH | 1 |
| Sogani, PC | 1 |
| Vagaiwala, MR | 1 |
| Whitmore, WF | 1 |
| Akaza, H | 1 |
| Usami, M | 1 |
| Kotake, T | 1 |
| Koiso, K | 1 |
| Aso, Y | 1 |
| Eisenberger, MA | 1 |
| Blumenstein, BA | 1 |
| Crawford, ED | 1 |
| Miller, G | 1 |
| McLeod, DG | 1 |
| Loehrer, PJ | 1 |
| Wilding, G | 1 |
| Sears, K | 1 |
| Culkin, DJ | 1 |
| Thompson, IM | 1 |
| Bueschen, AJ | 1 |
| Lowe, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Collection of Blood From Patients With Prostate Cancer[NCT00923221] | 1,000 participants (Anticipated) | Observational | 2007-02-28 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for flutamide and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cyprote | 2003 |
Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy.
Topics: Acid Phosphatase; Adenocarcinoma; Adult; Aged; Anilides; Bone Neoplasms; Clinical Trials as Topic; F | 1984 |
A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Chlormadinone Acetate; Confidence Intervals; Double-Blind M | 1993 |
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Combined Modal | 1998 |